Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid - Abstract

Published on 16 July 2012
  • Print

BACKGROUND: Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC).To read more, a FREE Urotoday registration is required. Click here to register or login above.
To read UIJ content, a separate subscription is required.

Tags: